Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

And another thing about Zenith 20 cohort 5. If, each of the 60 patients for the previously treated EGFR and HER2, and for 1st-line EGFR, or 180 pts in total, in cohort 5, is, as suggested by some, a 2nd trial needed for EU approval then think about them ONLY needing 60 patients instead of the 87 patients for cohort 1 and 2, and 70 for cohort 3. They are feeling highly confident, aren’t they.